Liquidia Corp CFO and COO Michael Kaseta reported an exercise-and-sell transaction in company stock. He exercised stock options covering a total of 133,789 shares of common stock at exercise prices ranging from $2.54 to $2.97 per share and then sold 133,789 shares at a volume-weighted average price of $40.2379 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025. After these transactions, he directly holds 411,855 shares of common stock, which include various blocks of unvested restricted stock units and shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.
Serendipity Biopharma LLC filed a Rule 144 notice reporting resale activity in common stock. The filing lists 10b5-1 sales: 25,000 shares sold on 04/09/2026 for $1,002,887.50 and an earlier sale of 66,610 shares on 01/12/2026 for $2,493,212.30. The broker listed is Morgan Stanley Smith Barney LLC and the filing references NASDAQ.
Michael Kaseta reported insider transactions including sales under a Rule 10b5-1 plan and an option exercise. The filing lists 10b5-1 sales on 04/09/2026, 03/02/2026, and 01/12/2026 with share counts and gross proceeds shown below. It also records an exercise of stock options for 23,821 shares on 04/10/2026 with cash consideration.
Serendipity Biopharma LLC files a Form 144 reporting proposed sales of Common Stock. The filing lists a proposed sale of 25,000 shares through Morgan Stanley Smith Barney LLC and discloses 66,610 shares sold during the prior three months. Transaction dates include 11/18/2020 and 01/12/2026.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice relating to 133,789 shares of Common stock tied to an exercise of stock options on 04/09/2026, with cash payment indicated. The excerpt also lists previous reported sales by Michael Kaseta: 1,165 shares on 03/02/2026 and 36,932 shares on 01/12/2026.
Canaan VIII, L.P., an investment fund associated with Liquidia director Stephen M. Bloch, sold 70,234 shares of Liquidia common stock in open-market transactions. The sales occurred on March 26–27 at weighted average prices ranging from about $35 to $37 per share across several trades.
After these sales, entities tied to the fund reported holding 2,188,935 shares indirectly, while Bloch also reported 65,712 shares held directly. Bloch disclaims beneficial ownership of the fund-held shares except for his pecuniary interest and did not participate in the investment decision due to a communications-screen policy.
Canaan VIII LP filed a Form 144 disclosing a proposed sale of 62,550 shares of Common Stock. The filing lists UBS Financial Services as the broker and records a prior sale of 7,684 shares on 03/26/2026.
Liquidia Corp Chief Commercial Officer Scott Moomaw exercised stock options and sold shares in a planned transaction. He exercised options to acquire 17,000 shares of common stock at $3.40 per share, then sold 17,000 shares at a volume-weighted average price of $36.8128 and an additional 1,314 shares at $36.48 in open-market trades.
The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on November 7, 2025, and represent the sale of shares underlying fully vested options. After these trades, he holds 187,640 shares directly, and his reported holdings include multiple tranches of unvested RSUs and 2,650 shares acquired under the employee stock purchase plan.
Liquidia Corp’s Chief Medical Officer Rajeev Saggar sold 35,365 shares of Common Stock in an open-market transaction. The shares were sold on March 13, 2026 at a volume-weighted average price of $36.3024, based on trades between $36.29 and $36.45.
After the sale, Saggar directly holds 174,473 shares of Liquidia, which include multiple blocks of unvested restricted stock units granted in 2023, 2024, and 2025, additional RSUs granted in 2026 that have not yet vested, and 2,213 shares acquired under the 2020 Employee Stock Purchase Plan.